Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib

详细信息查看全文

作者：Ken Woo^b ; ¹ ; Scott G. Stewart^a ; ¹ ; Geraldine S. Kong^a ; Megan L. Finch-Edmondson^a ; Benjamin J. Dwyer^a ; ^b ; Sing Y. Yeung^a ; Lawrence J. Abraham^a ; Sven S. Kampmann^a ; Luke A. Diepeveen^a ; ^b ; Adam M. Passman^a ; Caryn L. Elsegood^a ; ^d ; Janina E.E. Tirnitz-Parker^d ; ^f ; Bernard A. Callus^a ; ^g ; John K. Olynyk^c ; ^d ; ^e ; George C.T. Yeoh^a ; ^b ; ^{george.yeoh@uwa.edu.au" class="auth_mail" title="E-mail the corresponding author}
关键词：Liver cancer ; Progenitor cells ; Thalidomide ; Analogues ; Lenalidomide ; Sorafenib ; Apoptosis ; Mitosis
刊名：European Journal of Medicinal Chemistry
出版年：2016
出版时间：14 September 2016
年：2016
卷：120
期：Complete
页码：275-283
全文大小：1098 K

文摘

•: Thalidomide C1 selectively inhibits growth of tumorigenic liver progenitor cells.
•: Growth inhibition was achieve through the induction of apoptosis in treated cells.
•: Thalidomide C1 treatment did not consistently alter ERK signalling.
•: However non-canonical NFκB signalling consistently decreased following treatment.